Outcome of COVID-19 patients treated with and without monoclonal antibody – adalimumab, along with conventional antiviral therapy

Background- The current outbreak of viral pneumonia, caused by novel coronavirus SARS-CoV-2, is the focus of worldwide attention.Based on their mechanism of action and their demonstrated utility in chronic inflammatory conditions and early feasibility studies in COVID-19, there is a strong case for TNF inhibitor use in COVID-19. Objectives-To find out the Outcome of covid 19 patients treated with and without monoclonal antibody – Adalimumab, along with conventional antiviral therapy. Methods-A Retrospective case comparative study of 100 patients with COVID19 who were admitted in VMKVMCH COVID19 Ward, Salem from May 2021 to July 2021 was included in this study. Purposive sampling technique was used. Demographic details of the patients and outcomes were noted.SPSS (Version 22.0) was used. Results- Males were mostly affected (65%) as compared to females (35%), mean age was 49 years. Number of days in hospital stay was 8 days. Mortality was around 4%.RTPCR was the investigation of choice for the diagnosis of COVID done in 93% of patients and it was statistically significant (p<0.05), but due to severity of symptoms HRCT was the gold standard investigation. 97% has CORADS score greater than 5 and it was significant